FCGR3A and neoplasm: mAb interactions with FcγRIIa and FcγRIIIa mediate antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) by tumor targeting mAb such as Rituximab, Herceptin and Campath.